Epratuzumab: Phase II data

An open-label, U.S. Phase II trial in 57 evaluable patients with previously untreated follicular lymphoma showed that IV epratuzumab plus rituximab produced an ORR of 84%, including 19 complete responses and 29 partial responses, plus 9 cases of stable disease (SD). Mean time to complete response was 9 months, and 2 patients progressed after a period of SD. Data were presented at the American Society of Hematology meeting in Orlando. ...